All Stories

  1. Angioimmunoblastic T‐cell lymphoma after acute myeloid leukemia: Alleged common pathogenesis. A case report and literature review

    Article • Clinical Case Reports, November 2020, Wiley

    Dr Javier Loscertales

  2. CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia

    Article • Biomarker Research, October 2020, Springer Science + Business Media

    Dr Javier Loscertales

  3. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

    Article • Leukemia & Lymphoma, August 2020, Taylor & Francis

    Dr Javier Loscertales

  4. Clinical outcome and prognostic factors of patients with Richter syndrome: real‐world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)

    Article • British Journal of Haematology, June 2020, Wiley

    Dr Javier Loscertales

  5. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group

    Article • American Journal of Hematology, March 2020, Wiley

    Dr Javier Loscertales

  6. A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial

    Article • Leukemia & Lymphoma, February 2020, Taylor & Francis

    Dr Javier Loscertales

  7. Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

    Article • Pharmaceutical Research, May 2019, Springer Science + Business Media

    Dr Javier Loscertales

  8. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

    Article • Leukemia, October 2018, Springer Science + Business Media

    Dr Javier Loscertales

  9. Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in th...

    Article • Leukemia & Lymphoma, January 2018, Taylor & Francis

    Dr Javier Loscertales, Dr Shana B Traina, Graeme Fraser

  10. Actualización de las guías nacionales de consenso del Grupo Español de Leucemia Linfocítica Crónica para el tratamiento y seguimiento de la leucemia linfocítica crónica

    Article • Medicina Clínica, April 2017, Elsevier

    Dr Javier Loscertales

  11. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

    Article • The Lancet Haematology, March 2017, Elsevier

    Dr Javier Loscertales

  12. Randomized phase 2 study of otlertuzumab and bendamustineversusbendamustine in patients with relapsed chronic lymphocytic leukaemia

    Article • British Journal of Haematology, December 2016, Wiley

    Dr Javier Loscertales

  13. Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL

    Article • Leukemia & Lymphoma, November 2016, Taylor & Francis

    Dr Javier Loscertales

  14. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial

    Article • Leukemia & Lymphoma, October 2016, Taylor & Francis

    Dr Javier Loscertales

  15. CLL

    Article • ClinicoEconomics and Outcomes Research, September 2016, Dove Medical Press

    Dr Javier Loscertales

  16. The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial)

    Article • Bone Marrow Transplantation, May 2016, Springer Science + Business Media

    Dr Javier Loscertales

  17. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

    Article • The Lancet Oncology, February 2016, Elsevier

    Dr Javier Loscertales

  18. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma

    Article • European Journal Of Haematology, August 2015, Wiley

    Dr Javier Loscertales

  19. Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia

    Article • Cancer Immunology Immunotherapy, February 2015, Springer Science + Business Media

    Dr Javier Loscertales

  20. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts

    Article • Annals of Hematology, November 2014, Springer Science + Business Media

    Dr Javier Loscertales

  21. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch

    Article • British Journal of Haematology, August 2014, Wiley

    Dr Javier Loscertales

  22. PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

    Article • Blood, July 2014, American Society of Hematology

    Dr Javier Loscertales

  23. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)

    Article • Leukemia & Lymphoma, September 2013, Taylor & Francis

    Dr Javier Loscertales

  24. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification

    Article • Annals of Hematology, September 2012, Springer Science + Business Media

    Dr Javier Loscertales

  25. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

    Article • Blood, August 2012, American Society of Hematology

    Prof Mukhyaprana Prabhu, Dr Javier Loscertales

  26. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial

    Article • British Journal of Haematology, August 2012, Wiley

    Dr Javier Loscertales

  27. Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results

    Article • British Journal of Haematology, January 2012, Wiley

    Dr Javier Loscertales

  28. Effect of FCGR2A and FCGR3A variants on CLL outcome

    Article • Blood, November 2010, American Society of Hematology

    Dr Javier Loscertales

  29. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia

    Article • Experimental Hematology, September 2010, Elsevier

    Dr Javier Loscertales

  30. Clonal evolution in patients with chronic lymphocytic leukemia

    Article • Leukemia & Lymphoma, May 2010, Taylor & Francis

    Dr Javier Loscertales

  31. Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

    Article • Journal of Clinical Oncology, April 2010, American Society of Clinical Oncology (ASCO)

    Dr Javier Loscertales

  32. Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia

    Article • Journal of Clinical Oncology, September 2009, American Society of Clinical Oncology (ASCO)

    Dr Javier Loscertales

  33. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia

    Article • Journal of Leukocyte Biology, April 2006, Oxford University Press (OUP)

    Dr Javier Loscertales

  34. Darbepoetin α for the treatment of anemia in patients with myelodysplastic syndromes

    Article • Cancer, January 2006, Wiley

    Dr Javier Loscertales

  35. Pulmonary embolism in a patient with severe congenital deficiency for factor V during treatment with fresh frozen plasma

    Article • Haemophilia, May 2005, Wiley

    Dr Javier Loscertales

  36. Las estrategias de crecimiento de la industria química alemana en España, 1880–1936: exportación e inversión directa

    Article • Revista de Historia Económica / Journal of Iberian and Latin American Economic History, September 2001, Cambridge University Press

    Dr Javier Loscertales

  37. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia

    Article • Cancer, January 2001, Wiley

    Dr Javier Loscertales